Dr. Rebecca A. Sager Receives PICI's First Ever Young Investigator Award for Cancer Research

Dr. Rebecca A. Sager Awarded PICI's Inaugural Young Investigator Award

The Parker Institute for Cancer Immunotherapy (PICI) has celebrated a significant milestone in cancer research by announcing Dr. Rebecca A. Sager, MD, PhD, as the first recipient of its prestigious Conquer Cancer - Parker Institute for Cancer Immunotherapy Endowed Young Investigator Award. This award aims to support early-career investigators who are making strides in advancing innovative oncology research.

Dr. Sager currently serves as a urologic oncology fellow at the renowned Memorial Sloan Kettering Cancer Center and has gained recognition for her impactful research focused on tumor immunology. Specifically, she investigates how various treatments affect the tumor immune microenvironment in clear cell renal cell carcinoma (ccRCC).

The award reinforces Dr. Sager's commitment to improving treatment outcomes for patients suffering from kidney cancer. "I am extremely grateful for this award, which supports my journey toward establishing my independent research program," stated Dr. Sager. She explained that her research aims to develop more personalized treatment strategies, enhancing the quality of life for patients diagnosed with this challenging disease.

At the upcoming American Society of Clinical Oncology (ASCO) Annual Meeting set to occur from May 29 to June 2 in Chicago, Dr. Sager will be honored for her exceptional work. Her project, entitled "Modeling the effects of HIF2α inhibition on the ccRCC tumor microenvironment," specifically addresses the persistent treatment challenges associated with ccRCC. Through a combination of analysis of human tumor samples and specialized mouse models, Dr. Sager will examine how the inhibition of HIF2a influences immune cell behavior and the growth of blood vessels within tumors. This essential research may inform future clinical trials, further supporting the path toward personalized therapies for kidney cancer patients.

Dr. Karen E. Knudsen, CEO of PICI, expressed her enthusiasm stating, "Dr. Sager's innovative research in clear cell renal cell carcinoma exemplifies the type of forward-thinking, patient-centered science this award was created to support."

PICI's mission centers around the acceleration of breakthrough cancer therapies, and Dr. Sager's endeavors align seamlessly with these goals. The institute seeks to transform cancer treatment paradigms by uniting leading cancer centers into a collaborative effort, driving high-reward science aimed at turning cancer into a curable disease.

Since its establishment in 2016 under the vision of Sean Parker, PICI has reinforced its commitment to fostering a research environment that emphasizes collaboration, shared objectives, and collective data use. The organization has already supported over 1,000 researchers across its network and has raised more than $4 billion in capital, further driving the development of biotech ventures.

In closing, Dr. Sager's groundbreaking research holds promise not only for advancing scientific understanding of kidney cancer but also for ultimately enhancing therapeutic options available to patients facing this devastating diagnosis. As she embarks on this journey, the support provided by the PICI’s Endowed Young Investigator Award serves as a catalyst for her impactful work in the field of oncology, laying the groundwork for more effective, personalized treatment approaches and improved patient outcomes.

For more information on Dr. Sager's work and the Parker Institute for Cancer Immunotherapy, visit Parker Institute's official website.